Year archive

Kinarus Therapeutics Holding AG — 2025 filings

All 24 regulatory filings released by Kinarus Therapeutics Holding AG (KNRS) in 2025, sourced directly from the official regulator.

24 Filings

2025 Period

2025 filings (24)

Filing	Released	Lang
Curatis Holding AG announces CHF 1.2 million private placement with strategic investor Capital/Financing Update	2025-11-21	English
Curatis Holding AG announces CHF 1.2 million private placement with strategic investor Capital/Financing Update	2025-11-21	English
FDA minutes confirm positive outcome of meeting on 9. September 2025 Corticorelin on track for Phase 3 Regulatory Filings	2025-09-18	English
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3 Regulatory Filings	2025-09-18	English
Investor Presentation Investor Presentation	2025-09-18	English
Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01 Earnings Release H1 2025	2025-09-15	English
Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01 Earnings Release H1 2025	2025-09-15	English
Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues Regulatory Filings	2025-09-05	English
Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues Regulatory Filings	2025-09-05	English
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study Legal Proceedings Report	2025-07-31	English
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study Legal Proceedings Report	2025-07-31	English
Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors AGM Information	2025-05-25	English
Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors AGM Information	2025-05-24	English
Curatis discloses Corticorelin as active substance of C-PTBE-01 \| Market Opportunity in PTBE expected to exceed USD 1 billion \| Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog Regulatory Filings	2025-05-23	English
Curatis discloses Corticorelin as active substance of C-PTBE-01 \| Market Opportunity in PTBE expected to exceed USD 1 billion \| Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog Regulatory Filings	2025-05-23	English
Investor Presentation Investor Presentation	2025-05-23	English
Articles of Incorporation Governance Information	2025-05-02	German
Curatis: Umsatzwachstum von 30% im Vertrieb - dazu deutliche Ausweitung Patientenzielgruppe beim Lead-Projekt C-PTBE-01 Earnings Release FY 2024	2025-03-27	German
Curatis: Umsatzwachstum von 30% im Vertrieb - dazu deutliche Ausweitung Patientenzielgruppe beim Lead-Projekt C-PTBE-01 Earnings Release FY 2024	2025-03-27	German
Investor Presentation Investor Presentation	2025-03-27	English
Annual Report 2024 Annual Report FY 2024	2025-03-27	English
Curatis Announces Formation of Distinguished Advisory Board Board/Management Information	2025-03-12	English
Curatis Announces Formation of Distinguished Advisory Board Board/Management Information	2025-03-11	English
Curatis Announces Formation of Distinguished Advisory Board Board/Management Information	2025-03-11	English